Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma

CD30 and programmed cell death protein 1 (PD-1) are two ideal therapeutic targets in classical Hodgkin lymphoma (cHL). The CD30 antibody-drug conjugate (ADC) brentuximab vedotin and the PD-1 antibodies nivolumab and pembrolizumab are highly efficacious in treating relapsed and/or refractory cHL. Ong...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yucai, Nowakowski, Grzegorz S., Wang, Michael L., Ansell, Stephen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914042/
https://www.ncbi.nlm.nih.gov/pubmed/29685160
http://dx.doi.org/10.1186/s13045-018-0601-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914042/
https://www.ncbi.nlm.nih.gov/pubmed/29685160
http://dx.doi.org/10.1186/s13045-018-0601-9

Ejemplares similares